ID

34394

Descrição

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms; ODM derived from: https://clinicaltrials.gov/show/NCT01309789

Link

https://clinicaltrials.gov/show/NCT01309789

Palavras-chave

  1. 17/01/2019 17/01/2019 -
Titular dos direitos

see on clinicaltrials.gov

Transferido a

17 de janeiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
Descrição

ID.1

Tipo de dados

boolean

measurable disease of at least 1.5 cm
Descrição

ID.2

Tipo de dados

boolean

ecog performance status less than or equal to 2
Descrição

ID.3

Tipo de dados

boolean

Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
Descrição

ID.4

Tipo de dados

boolean

current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
Descrição

ID.5

Tipo de dados

boolean

history of another primary malignancy that has not been in remission for at least 3 years
Descrição

ID.6

Tipo de dados

boolean

left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
Descrição

ID.7

Tipo de dados

boolean

viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
Descrição

ID.8

Tipo de dados

boolean

known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
Descrição

ID.9

Tipo de dados

boolean

Similar models

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
boolean
ID.2
Item
measurable disease of at least 1.5 cm
boolean
ID.3
Item
ecog performance status less than or equal to 2
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
boolean
ID.5
Item
current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
boolean
ID.6
Item
history of another primary malignancy that has not been in remission for at least 3 years
boolean
ID.7
Item
left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
boolean
ID.8
Item
viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
boolean
ID.9
Item
known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
boolean

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial